Atara Biotherapeutics said it has scheduled a Type A meeting with the U.S. Food and Drug Administration to discuss the agency’s Complete Response Letter for the EBVALLO biologics license application for tabelecleucel, which the FDA issued on Jan. 9, 2026. The update signals the company is continuing regulatory discussions as it works to address issues raised by the FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-103127), on March 12, 2026, and is solely responsible for the information contained therein.